Australia - engelsk - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - tazobactam sodium, quantity: 537 mg (equivalent: tazobactam, qty 500 mg); ceftolozane sulfate, quantity: 1147 mg (equivalent: ceftolozane, qty 1000 mg) - injection, powder for - excipient ingredients: arginine; sodium chloride; citric acid - zerbaxa (ceftolozane/tazobactam) is indicated for the treatment of the following infections in adults suspected or proven to be caused by designated susceptible microorganisms: - complicated intra-abdominal infections in combination with metronidazole - complicated urinary tract infections, including pyelonephritis - nosocomial pneumonia, including ventilator-associated pneumonia (vap),consideration should be given to published therapeutic guidelines on the appropriate use of antibacterial agents.

Israel - engelsk - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - ceftolozane as sulfate; tazobactam as sodium - powder for concentrate for solution for infusion - tazobactam as sodium 0.5 g; ceftolozane as sulfate 1 g - ceftolozane and enzyme inhibitor - zerbaxa is indicated for the treatment of the following infections in adults:-complicated intra abdominal infections;-acute pyelonephritis caused by pathogens resistant to other treatments as confirmed by urine culture-complicated urinary tract infections.-hospital-acquired pneumonia (hap), including ventilator-associated pneumonia (vap).consideration should be given to official guidance on the appropriate use of antibacterial agents

USA - engelsk - NLM (National Library of Medicine)

merck sharp & dohme llc - ceftolozane sulfate (unii: 7r247u84hy) (ceftolozane - unii:37a4ies95q), tazobactam sodium (unii: uxa545abtt) (tazobactam - unii:se10g96m8w) - ceftolozane 1 g in 10 ml - zerbaxa used in combination with metronidazole is indicated for the treatment of adult and pediatric patients (birth to less than 18 years old) with complicated intra-abdominal infections (ciai) caused by the following susceptible gram-negative and gram-positive microorganisms: enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, proteus mirabilis, pseudomonas aeruginosa, bacteroides fragilis, streptococcus anginosus, streptococcus constellatus, and streptococcus salivarius . zerbaxa is indicated for the treatment of adult and pediatric patients (birth to less than 18 years old) with complicated urinary tract infections (cuti), including pyelonephritis, caused by the following susceptible gram-negative microorganisms: escherichia coli , klebsiella pneumoniae , proteus mirabilis , and pseudomonas aeruginosa . zerbaxa is indicated for the treatment of adult patients (18 years and older) with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/

Den europeiske union - fransk - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - ceftolozane de sulfate, de tazobactam sodique - infections bactériennes - les antibactériens à usage systémique, - zerbaxa is indicated for the treatment of the following infections in adults:complicated intra abdominal infections;acute pyelonephritis;complicated urinary tract infections;hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap). la considération devrait être donnée à des recommandations officielles concernant l'utilisation appropriée des antibactériens.

Den europeiske union - dansk - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - ceftolozane sulfat, natrium tazobactam - bakterieinfektioner - antibakterielle midler til systemisk brug, - zerbaxa is indicated for the treatment of the following infections in adults:complicated intra abdominal infections;acute pyelonephritis;complicated urinary tract infections;hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap). det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..

Israel - engelsk - Ministry of Health

merck sharp & dohme israel ltd - ceftolozane as sulfate; tazobactam as sodium - powder for concentrate for solution for infusion - tazobactam as sodium 0.5 g; ceftolozane as sulfate 1 g - ceftolozane and enzyme inhibitor - zerbaxa is indicated for the treatment of the following infections in adults:-complicated intra abdominal infections;-acute pyelonephritis caused by pathogens resistant to other treatments as confirmed by urine culture-complicated urinary tract infections.-hospital-acquired pneumonia (hap), including ventilator-associated pneumonia (vap).consideration should be given to official guidance on the appropriate use of antibacterial agents

USA - engelsk - NLM (National Library of Medicine)

steri-pharma, llc - ceftolozane sulfate (unii: 7r247u84hy) (ceftolozane - unii:37a4ies95q) - ceftolozane 1 g in 10 ml

Den europeiske union - maltesisk - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - ceftolozane sulfate, tazobactam sodium - infezzjonijiet batteriċi - antibatteriċi għal użu sistemiku, - zerbaxa is indicated for the treatment of the following infections in adults:complicated intra abdominal infections;acute pyelonephritis;complicated urinary tract infections;hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap). għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - ceftolozane sulfate 1147mg equivalent to ceftolozane 1000 mg; tazobactam sodium 537mg equivalent to tazobactam 500 mg - powder for injection - 1000mg/500mg - active: ceftolozane sulfate 1147mg equivalent to ceftolozane 1000 mg tazobactam sodium 537mg equivalent to tazobactam 500 mg excipient: arginine citric acid sodium chloride - zerbaxa (ceftolozane/tazobactam) is indicated for the treatment of the following infections in adults and paediatric (birth to less than 18 years of age) patients with the following infections caused by designated susceptible microorganisms: - complicated intra-abdominal infections in combination with metronidazole. - complicated urinary tract infections, including pyelonephritis. consideration should be given to published therapeutic guidelines on the appropriate use of antibacterial agents.

Den europeiske union - engelsk - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - ceftolozane sulfate, tazobactam sodium - bacterial infections - antibacterials for systemic use, - zerbaxa is indicated for the treatment of the following infections in adults:complicated intra abdominal infections;acute pyelonephritis;complicated urinary tract infections;hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap).consideration should be given to official guidance on the appropriate use of antibacterial agents.